Jiangsu Hengrui Medicine Co., Ltd. - Product Pipeline Review - 2015

Published: May, 2015 | Pages: 44 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Jiangsu Hengrui Medicine Co., Ltd. - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'Jiangsu Hengrui Medicine Co., Ltd. - Product Pipeline Review - 2015', provides an overview of the Jiangsu Hengrui Medicine Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Jiangsu Hengrui Medicine Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Jiangsu Hengrui Medicine Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Jiangsu Hengrui Medicine Co., Ltd.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Jiangsu Hengrui Medicine Co., Ltd.'s pipeline products

Reason to Buy

- Evaluate Jiangsu Hengrui Medicine Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Jiangsu Hengrui Medicine Co., Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Jiangsu Hengrui Medicine Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Jiangsu Hengrui Medicine Co., Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Jiangsu Hengrui Medicine Co., Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of Jiangsu Hengrui Medicine Co., Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Jiangsu Hengrui Medicine Co., Ltd. Snapshot 5
Jiangsu Hengrui Medicine Co., Ltd. Overview 5
Key Information 5
Key Facts 5
Jiangsu Hengrui Medicine Co., Ltd. - Research and Development Overview 6
Key Therapeutic Areas 6
Jiangsu Hengrui Medicine Co., Ltd. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Jiangsu Hengrui Medicine Co., Ltd. - Pipeline Products Glance 13
Jiangsu Hengrui Medicine Co., Ltd. - Late Stage Pipeline Products 13
Phase III Products/Combination Treatment Modalities 13
Jiangsu Hengrui Medicine Co., Ltd. - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
Jiangsu Hengrui Medicine Co., Ltd. - Early Stage Pipeline Products 16
Preclinical Products/Combination Treatment Modalities 16
Jiangsu Hengrui Medicine Co., Ltd. - Drug Profiles 17
apatinib 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
carvedilol phosphate ER 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
SHR-1020 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
SP-2086 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
ivabradine hydrochloride SR 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
HHGV-678 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
PEX-168 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
remimazolam 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
SHR-117887 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Pyrotinib 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Hetrombopag Olamine 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
SHR-0302 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
XB-2202 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Jiangsu Hengrui Medicine Co., Ltd. - Pipeline Analysis 34
Jiangsu Hengrui Medicine Co., Ltd. - Pipeline Products by Target 34
Jiangsu Hengrui Medicine Co., Ltd. - Pipeline Products by Route of Administration 36
Jiangsu Hengrui Medicine Co., Ltd. - Pipeline Products by Molecule Type 37
Jiangsu Hengrui Medicine Co., Ltd. - Pipeline Products by Mechanism of Action 38
Jiangsu Hengrui Medicine Co., Ltd. - Recent Pipeline Updates 40
Jiangsu Hengrui Medicine Co., Ltd. - Dormant Projects 41
Jiangsu Hengrui Medicine Co., Ltd. - Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 43
Disclaimer 44

List of Tables

Jiangsu Hengrui Medicine Co., Ltd., Key Information 5
Jiangsu Hengrui Medicine Co., Ltd., Key Facts 5
Jiangsu Hengrui Medicine Co., Ltd. - Pipeline by Indication, 2015 8
Jiangsu Hengrui Medicine Co., Ltd. - Pipeline by Stage of Development, 2015 9
Jiangsu Hengrui Medicine Co., Ltd. - Monotherapy Products in Pipeline, 2015 10
Jiangsu Hengrui Medicine Co., Ltd. - Partnered Products in Pipeline, 2015 11
Jiangsu Hengrui Medicine Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2015 12
Jiangsu Hengrui Medicine Co., Ltd. - Phase III, 2015 13
Jiangsu Hengrui Medicine Co., Ltd. - Phase II, 2015 14
Jiangsu Hengrui Medicine Co., Ltd. - Phase I, 2015 15
Jiangsu Hengrui Medicine Co., Ltd. - Preclinical, 2015 16
Jiangsu Hengrui Medicine Co., Ltd. - Pipeline by Target, 2015 35
Jiangsu Hengrui Medicine Co., Ltd. - Pipeline by Route of Administration, 2015 36
Jiangsu Hengrui Medicine Co., Ltd. - Pipeline by Molecule Type, 2015 37
Jiangsu Hengrui Medicine Co., Ltd. - Pipeline Products by Mechanism of Action, 2015 39
Jiangsu Hengrui Medicine Co., Ltd. - Recent Pipeline Updates, 2015 40
Jiangsu Hengrui Medicine Co., Ltd. - Dormant Developmental Projects,2015 41
Jiangsu Hengrui Medicine Co., Ltd., Subsidiaries 42